ArticleWorld journal of gastroenterology2025
Important role of tumor deposits and negative lymph nodes in prognosis of N1c colorectal cancer patients.
Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic impact of tumor deposits in colorectal cancer.World journal of gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe number of tumor deposits (TDs) does not play a part in the current tumor node metastasis staging. Negative lymph node (NLN) status is associated with the prognosis of colorectal cancer (CRC), but its clear role in N1c stage remains to be defined.
aimTo evaluate the combination of TDs and NLNs as potential prognostic indicators in N1c CRC.
methodsWe retrospectively identified 107 consecutive patients who had N1c CRC radically resected at China-Japan Friendship Hospital. The combination of TDs and NLNs was calculated by the formula NLNTD = NLN/(TD + 1). Cutoff values of NLNs and NLNTD were determined using the R package "survminer". Disease-free survival (DFS), overall survival (OS) and cancer-specific survival (CSS) were determined using the Kaplan-Meier method to assess the impact of NLNTD on prognosis. Results were compared using the log-rank test.
resultsThe median follow-up time was 63.17 (45.33-81.37) months for DFS, with 33.64% (36/107) of patients experiencing recurrence during follow-up. Five-year DFS was 66.0% (57.3%-76.0%). There was no significant difference in prognosis between patients with > 12 and ≤ 12 NLNs (
conclusionNLNTD could serve as important prognostic factor for outcomes in N1c CRC patients. These patients could be stratified for prognosis through NLNTD and the high-risk should be given more attention during treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.